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StochaStic Modeling of tuMor 
ProgreSSion: gi tract cancerS aS 
a ParadigM
Historically, the founding paradigm has been 
that cancers of the gastrointestinal tract are 
preceded by a pre-invasive stage of intraepi-
thelial neoplasia. From the morphological 
standpoint the term “dysplasia” has been 
conventionally applied to the collection of 
changes in cellular morphology and tissue 
architecture that define intraepithelial neo-
plasia. Although morphologically different 
according to the specific GI tract anatomic 
location (Barrett-associated, gastritis- and 
non-gastritis-associated, adenomatous and 
serrated dysplasia; Odze et al., 2010) the sever-
ity of intraepithelial neoplasia is estimated 
from the degree of deviation from the normal 
tissue of origin, and the neoplastic process has 
been thought to progress univocally toward 
carcinoma through dysplasia of increasing 
severity. There now exists evidence to con-
strue the natural history of tumor progression 
in GI tract in accordance with a stochastic 
model, in which each stage is probabilistically 
linked with different evolutive pathways (pro-
gression, stabilization, regression) rather than 
deterministically associated with the onset of 
carcinoma (Risio, 2010). Moreover, even if 
biological reasons support dysplasia as the 
most predictive marker of the cancerization 
risk, the links between non-morphological 
features of precursors and their malignant 
transformation is greater than the one link-
ing dysplasia and malignancy, at least in the 
colonic carcinogenesis. New biomarkers are 
therefore needed, to define the magnitude 
of risk and the times of progression for each 
step of tumorigenesis, in order to ration-
ally schedule surveillance and follow-up of 
patients with diagnosed GI tract neoplasia 
and to plan suitable population-based cancer 
prevention interventions.
equivocal cancer PrecurSorS: old 
MiMickerS or new entitieS?
“Origin of Colorectal Cancers in Hyperplastic 
Polyps and Serrated Adenomas: Another 
Truism Bites the Dust” was the title-page 
of the Editorial by Hamilton (2001). Ten 
years later we are fully aware of those 
serrated polyps, mainly with sessile con-
figuration that, though obscured by a low 
histopathologic diagnostic reproducibility 
(Vieth et al., 2011), subtly mimic the inno-
cent, non-cancerous, hyperplastic polyps. 
Knowledge has also been gained about the 
molecular machinery driving and sustain-
ing the growth of sessile serrated lesions: 
they are unlikely to progress (at any rate 
with a low evolutive speed) toward cancer. 
Worries persist however, considering that a 
subset of these lesions appears to give rise 
to carcinoma when less than a few millim-
eters in size and, most importantly, that the 
vast majority of interval colon cancers are 
more likely than non-interval colon can-
cers to arise from serrated lesions (Sawhney 
et al., 2006).
Two critical issues, which need to be spe-
cifically addressed, are the following:
(i) To profile the morphological and/
or genetic phenotype of the serrated 
lesions actually engaged in the “serra-
ted polyp neoplasia pathway”;
(ii) To standardize the effective use of 
the new endoscopic techniques (e.g.,: 
magnifying chromoendoscopy) in 
order to improve the detection rates of 
those not easily identifiable GI cancer 
precursors, such as sessile serrated and 
non-polypoid adenomatous lesions.
at the interSection between 
hereditary and SPoradic 
neoPlaSia: faMilial cancerS
Familial cancers account for nearly 25% 
of all GI tract cancers and are a heteroge-
neous group encompassing patients with 
seemingly sporadic tumors that aggregate 
in families, in the absence of true and rec-
ognized hereditary syndromes (Castells 
et al., 2009). While the well-established 
hereditary syndromes feature a Mendelian 
inheritance pattern, familial cancers are 
likely to be a consequence of the co-inher-
itance of multiple, low-penetrance variants, 
 susceptibility genes that confer predispo-
sition to cancers. Non-syndromic familial 
cancers require, according to the familial 
risk stratification, specific diagnostic, ther-
apeutic, and preventive strategies, not com-
pletely defined yet. Cancer risk, however, is 
the result of complex interactions between 
genetic and non-genetic (lifestyle/dietary) 
risk factors. Epidemiological studies have 
identified several dietary risk factors for 
both gastric and colorectal neoplasia and 
common genetic variants are likely to inter-
act with them to modify the overall risk. 
On the other hand, assessing the interplay 
between inherited and non-genetic factors 
could turn out predictive of the effective-
ness of chemoprevention interventions 
and micronutrient supplementations 
(Tomlinson et al., 2010). In this setting, 
non-syndromic familial GI tract cancers are 
likely to become a privileged scenario for 
personalized, predictive medicine (Castells 
et al., 2009).
early cancer: refining the 
curative endoScoPic treatMent
To ensure the curative potential of endo-
scopic resection of gastrointestinal early 
cancers, treatment should be limited to 
lesions with no or minimal risk of meta-
static diffusion. Combining polypectomy, 
mucosal resection and, more recently, sub-
mucosal dissection more than half of GI 
cancers in early stages can be endoscopi-
cally removed (Kakushima and Fujishiro, 
2008). En bloc resection of neoplasms is 
crucial in that it allows the precise histo-
pathologic evaluation of the specimen in 
order to stratify the treatment outcomes 
and the patient’s prognosis. Here however, 
we are acting according to empiric rather 
than heuristic criteria. Evidence is lack-
ing, at the current time concerning the 
minimal distance cancer border- resection 
margins defining the R0 endoscopic 
removal, on which the recurrence rates of 
the lesions depend. Similarly, the minimal 
depth of colonic submucosa cancer inva-
sion associated with metastatic  potential 
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2008). The availability of innovative screen-
ing tests, together with the combinations of 
different screening intervals and selectively 
targeted risk groups, results in an excit-
ing scenario, promoting, and intensifying 
the research to optimize colorectal cancer 
screening programs.
We believe these frontiers worthy of 
being focused, investigated, discussed, and 
criticized. Frontiers in GI cancers is aimed 
at supporting multidisciplinary research to 
speed up clinical applications of biological 
advances. Manuscripts are welcomed, there-
fore, dealing with tumorigenesis, preven-
tion, early detection, and treatment of GI 
tract neoplasia.
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of rectal cancer and transferable to clini-
cal practice. Among the limiting factors, 
the lack of reliable clinical diagnostic 
tools to accurately predict the pathologi-
cal tumor response plays a role. In effect, 
preoperative radiology has been shown to 
overestimate down staging of the tumor and 
pathologic evaluation of the resected speci-
mens remains the best and most accurate 
method for assessing pathologic response 
to preoperative chemoradiation in rectal 
(Glynne-Jones et al., 2008), esophageal 
(Wu et al., 2007) primaries, and in colo-
rectal liver metastases (Rubbia-Brandt 
et al., 2007). None of the histopathologi-
cal classifications of carcinoma response to 
neo-adjuvant therapies, however, consider 
the viability of the residual, morphologi-
cally identifiable neoplastic cells, which is 
the real predictor of tumor re-growth and 
progression. Consequently, investigations 
should be aimed at:
– Defining finely tuned histopathologic 
features (apoptosis, necroptosis, can-
cer stem cell niches) to be related to the 
specific integrated therapies and esta-
blishing histological tumor regression 
grading systems specific for these the-
rapeutic modalities.
– Designing appropriate clinical vali-
dation studies in regard to long-term 
outcomes and clinical vs pathological 
complete response concordance.
controlling cancer: the eMerging 
role of Screening PrograMS
Although the substantial improvement in 
survival derived from the new treatments 
and primary prevention bears potential on 
the long run, screening so far seems to offer 
the best possibility for reducing colorectal 
cancer mortality. While few screening tests 
have been proven effective in reducing colo-
rectal cancer incidence (sigmoidoscopy) 
and mortality (FOBT and sigmoidoscopy; 
Segnan et al., 2011), others (stool DNA, 
Computed Tomographic Colonography) 
need to be further investigated and evalu-
ated in terms of effectiveness and cost/
effectiveness. Microstimulation models 
have been built up depicting the transition 
probabilities, duration in states and time 
of events throughout the growth, and the 
malignant transformation of adenomas 
useful to define the appropriate ages and 
intervals for cancer screening (Zauber et al., 
that is of paramount importance in pre-
dicting long-term outcomes has to be 
defined yet.
targeting geneS, PathwayS, and 
networkS: knotS in biological 
theraPieS
Constitutive activation of the EGFR/RAS/
PI3K cell-signaling pathway due to gene 
somatic mutations in core pathway compo-
nents occurs in GI tract cancers and needs 
predictive biomarkers of response to the 
biological therapies specifically targeting this 
pathway. In this way, EGFR-targeted mono-
clonal antibody therapies (such as cetuximab 
and panitumumab) are undergoing exten-
sive clinical evaluation in recurrent or first 
line metastatic colorectal cancer, mutational 
status of KRAS and BRAF genes providing 
the predictive markers for anti-EGFR ther-
apy resistance. Similarly, the monoclonal 
antibody against VEGFR, bevacizumab, in 
combination with 5-FU/leucovorin and/or 
irinotecan has been shown to improve sur-
vival of patients with advanced colorectal 
cancer, although reliable predictive markers 
are not available yet. Such a single gene–based 
approach has driven the research during the 
last years, in spite of its well known methodo-
logical and conceptual restrictions. Cancer 
heterogeneity represents a major concern 
in testing predictive biomarkers, in that the 
clonal expansion and the intratumor spatial 
distribution of emerging subclones are not 
currently predictable, impairing the sensitiv-
ity of tissue-based essays. Most importantly, 
cancer genome operates as a whole biological 
system due to the functional role of cancer 
genes exerted through their mutual, RNA, 
microRNAs, and protein–DNA interac-
tions, comprehensively included under the 
categories of transcriptomes and interac-
tomes. (Network modeling, to be pursued 
by the forthcoming translational research is 
needed to optimize the effectiveness of bio-
logical targeting of cancer cells in an indi-
vidual tumor. The aim is to move from the 
traditional “trial and error” toward a person-
alized approach also in the adjuvant setting 
(Deschoolmeester et al., 2010).
aSSociationS and effectS: what 
and how to MeaSure in 
MultiModal treatMentS
Despite intensive and focused research no 
biomarkers have been found which are pre-
dictive of responsiveness to  chemoradiation 
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